Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Advanced Solid Tumors
Phase PHASE1
Enrollment 138
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Drug: M7437 — Participants will receive M7437 as an intravenous infusion at a dose corresponding to their assigned cohort. Dose escalation will occur between cohorts, with 3-4 participants enrolled at each dose level before proceeding to the next higher dose.
  • Drug: M7437 — Participants will receive M7437 at a dose that was determined as recommended dose for expansion (RDE) in Part 1.

Primary Outcomes

  • Dose-escalation Cohort: Occurences of Dose Limiting Toxicities (DLTs) (DLT period is 21 days (cycle 1))
  • Dose-escalation Cohort: Number of Participants With Treatment-Emergent Adverse Event (TEAEs) and Adverse Event (AEs) (Up to end of Part 1 of study (approximately 1 year 8 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-02-13
Completion: 2029-03-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 138 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Principal Investigators:
  • Medical Responsible (STUDY_DIRECTOR) - EMD Serono Research & Development Institute, Inc.
Contact Information
Study Contact:
US Medical Information
888-275-7376
eMediUSA@emdserono.com
Communication Center
+49 6151 72 5200
service@emdgroup.com
203-785-6221
Yale University - Yale University School of Medicine
Interventions
  • Drug: M7437 — Participants will receive M7437 as an intravenous infusion at a dose corresponding to their assigned cohort. Dose escalation will occur between cohorts, with 3-4 participants enrolled at each dose level before proceeding to the next higher dose.
  • Drug: M7437 — Participants will receive M7437 at a dose that was determined as recommended dose for expansion (RDE) in Part 1.
Study Locations (9 sites)
Yale University - Yale University School of Medicine, New Haven, Connecticut 06510 United States
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville, North Carolina 28078 United States
NEXT Houston, Galveston, Texas 77001 United States
NEXT Oncology - PARENT, San Antonio, Texas 78229 United States
Princess Margaret Cancer Centre, Toronto, Canada
BC Cancer - Vancouver - BC Cancer Agency, Vancouver, Canada
National Cancer Center Hospital, Tokyo, Japan
Hospital Universitari Vall d'Hebron - VHIO - Oncology - Phase I Unit, Barcelona, 08035 Spain
NEXT Madrid - Hospital Universitario Quironsalud Madrid, Madrid, Spain
Eligibility Criteria
Inclusion Criteria: * Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standard therapies, or for which no standard therapy is judged appropriate by the Investigator. For each tumor type, participants have received prior lines of therapy, where locally available: * Non-small cell lung cancer (nonsquamous or squamous) * Triple-negative breast cancer * Squamous cell carcinoma of head and neck * Pancreatic ductal adenocarcinoma * Gastric cancer * Epithelial ovarian cancer * Participants with ECOG Performance Status (ECOG) less than and equal to (\<=) 1 * Participants must have blood, liver, and kidney function within safe levels. * Other protocol defined inclusion criteria may apply Exclusion Criteria: * Participant has a history of another malignancy within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, benign prostate neoplasm/hyperplasia, or malignancy that in the opinion of the Investigator, with concurrence with the Sponsor's Medical Monitor, is considered cured with minimal risk of recurrence within 3 years before the date of enrollment). History of hematopoietic allogenic transplantation. * Participants with known brain metastases, except those meeting both of the following criteria: 1. All brain metastases have been treated locally and are clinically stable for at least 4 weeks prior to the start of treatment. 2. No ongoing neurological symptoms that are related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable). * Participants with diarrhea (liquid stool) or ileus Grade more than (\>) 1 within 1 week of Cycle1Day1. * Participants with active chronic inflammatory bowel disease and/or bowel obstruction. * Participants with history of serious gastrointestinal bleeding within 3 months of Cycle1Day1. * Other protocol defined exclusion criteria may apply.
Conditions Open Angle Glaucoma, Ocular Hypertension
Phase PHASE4
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution — Subjects will receive netarsudil-latanoprost fixed combination ophthalmic solution 0.02%/0.005% in one eye and compare it to latanoprost 0.005% in the contralateral eye
  • Drug: Latanoprost 0.005% Ophthalmic Solution — latanoprost 0.005% solution will be applied in the contralateral eye, once daily, QD (PM) for 14 days

Primary Outcomes

  • Change in mean Intraocular Pressure (IOP) (Change in mean IOP after 2 weeks of treatment with Latanoprost compared to baseline)
  • Change in mean IOP (Change in mean IOP after 2 weeks of treatment with Rocklatan compared to baseline)
  • Change in mean IOP (Change in mean IOP from baseline after 2 weeks of treatment with latanoprost minus change in mean IOP from baseline after 2 weeks of treatment with Rocklatan)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2025-11-21
Completion: 2027-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: Alcon Research
Principal Investigators:
  • Arthur J Sit, MD, MS (PRINCIPAL_INVESTIGATOR) - Mayo Clinic
Contact Information
Study Contact:
Bridgette Halder
507-422-2780
Halder.Bridgette@mayo.edu
Bridgette Halder
507-422-2780
Mayo Clinic in Rochester
Arthur J Sit, MD, MS
Mayo Clinic in Rochester
Interventions
  • Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution — Subjects will receive netarsudil-latanoprost fixed combination ophthalmic solution 0.02%/0.005% in one eye and compare it to latanoprost 0.005% in the contralateral eye
  • Drug: Latanoprost 0.005% Ophthalmic Solution — latanoprost 0.005% solution will be applied in the contralateral eye, once daily, QD (PM) for 14 days
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria * Diagnosis of OHT or mild-to-moderate OAG in both eyes (OAG in one eye and OHT in the fellow eye is acceptable) based on VF, OCT and dilated fundus examination within one year of the screening visit. * Both eyes must qualify for the study with an IOP of ≥18 mmHg but ≤34 mmHg on history or at the screening visit * Be able and willing to provide signed informed consent and follow study instructions * Ability to cooperate with the examinations required for the study and be able to attend all study visits * If a contact lens wearer, willing to remove contact lenses at least 24 hours prior to each of the study visits. * Best-corrected visual acuity (BCVA) using ETDRS chart of +0.4 logMAR units (Snellen equivalent \~ 20/50) or better in each eye Exclusion Criteria Ocular: * Subjects with narrow angles (3 quadrants with Grade 2 or less according to Shaffer Scale), angle closure or a history of angle closure, or peripheral iridotomy in either eye * Severe glaucomatous damage * Difference in IOP between eyes \> 4 mmHg (unmedicated) at any baseline time point * Use of more than two ocular hypotensive medications within 30 days of screening * Chronic or recurrent inflammatory eye diseases in either eye * Ocular infection or ocular inflammation in the past 3 months in either eye * Ocular trauma other than corneal abrasion within the past 6 months in either eye * Clinically significant retinal disease (e.g., severe diabetic retinopathy, exudative or severe non-exudative macular degeneration, macular edema, retinal vein or artery occlusion) in either eye * Cornea pathologic changes preventing reliable measurement (e.g., scarring, opacity, edema, keratoconus) in either eye * Myopia greater than -6.00D, or hyperopia greater than +2.00D in either eye * Central corneal thickness less than 480 μm or greater than 620 μm in either eye * Previous intraocular surgery other than routine uncomplicated cataract surgery in either eye * Previous glaucoma intraocular surgery or glaucoma laser procedures (except SLT performed more than 6 months ago) in either eye * Unilateral intraocular surgery or glaucoma laser procedures * Previous corneal refractive surgery in either eye (eg, radial keratotomy, PRK, LASIK, corneal cross-linking, etc.) * Severe dry eye in either eye * Use of ocular medications in either eye within 30 days of screening, with the exception of IOP-lowering medications (which must be washed out according to the provided schedule), and lubricating drops for dry eye (which may be used throughout the study) * Known hypersensitivity to any component of the formulation (eg, benzalkonium chloride, etc.), or to topical anesthetic Systemic: * Clinically significant systemic diseases which might interfere with the study * Participation in any interventional study within 30 days prior to screening visit * Changes of systemic medication that could have an effect on IOP within 30 days prior to screening, or anticipated during the study including, β-adrenergic antagonists, α-adrenergic agonists and antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor blockers * Recent change in medications that are known to affect IOP within 30 days prior to the screening visit and during the study including: systemic/inhaled steroids, calcium channel blockers, diuretics, and vasodilators * Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative pregnancy test result at the screening examination and must not intend to become pregnant during the study * Subjects with a known hypersensitivity or contraindications to any of the ingredients in the study medications
Conditions Hysterectomy, Anxiety, Depression, Catas...
Phase NA
Enrollment 156
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this interventional clinical trial involving minimal risks and constraints is to evaluate whether an innovative approach to managing catastrophizing in the preoperative context of hysterectomy improves psychological outcomes compared to usual care in women of childbearing age who have been informed of an indication for hysterectomy. The main questions it aims to answer are: * Does the use of a personal narrative book improve adaptive emotional regulation and reduce catastrophizing, anxiety, and depressive symptoms in the preoperative period? * Does this intervention improve postoperative patient satisfaction and reduce the need for additional supportive measures? Researchers will compare standard care (CNGOF information leaflet with psychological consultation if needed) with an intervention including a personal narrative book in addition to standard care, to see if the intervention improves emotional regulation, psychological well-being, and satisfaction. Participants will: * provide explicit oral informed consent; * complete questionnaires on their emotional and psychological experience; * read a personal narrative book if they are randomized to the intervention group.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: personal narrative book — Reading a personal narrative book written by a patient who underwent a hysterectomy

Primary Outcomes

  • Adaptive regulation (between inclusion (D0) and surgery (S0), occurring 1 to 3 months later.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-13
Completion: 2028-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 156 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI)
Contact Information
Study Contact:
Dr. Adrien Crestani
07 85 30 63 45
recherche@ifemendo.fr
Clinique Tivoli-Ducos
Dr. Nicolas Carrabin
04 72 32 30 22
fse-carrabin@clinique-charcot.fr
Clinique Charcot
Dr. Anne-Sophie Boudy
05 62 21 39 54
asboudy@clinique-pasteur.com
Clinique Pasteur Toulouse
Interventions
  • Other: personal narrative book — Reading a personal narrative book written by a patient who underwent a hysterectomy
Study Locations (4 sites)
Clinique Tivoli-Ducos, Bordeaux, 33000 France
Clinique Charcot, Sainte-Foy-lès-Lyon, 69110 France
Clinique Pasteur Toulouse, Toulouse, 31076 France
Clinique St Cyprien Rive Gauche, Toulouse, 31330 France
Eligibility Criteria
Inclusion Criteria: * Women aged 18 years or older and under 43 years of age * Patients with an indication for hysterectomy for a non-malignant condition * Patients who have provided explicit oral consent to participate * Patients covered by the French social security system * Patients able to read and understand French and capable of reading a French book within a timeframe compatible with the study schedule Exclusion Criteria: * Women with suspected uterine cancer or high-grade dysplasia * Women participating or having participated to an interventional clinical trial within the 30 days prior to inclusion * Pregnant, breastfeeding, or parturient women * Protected patient: adults under guardianship or other legal protection; persons deprived of liberty by judicial or administrative order; persons hospitalized without consent * Patients with insufficient proficiency in the French language
Conditions Female Breast Cancer, Prostate Cancer, C...
Phase NA
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing among African Americans at risk for heredity cancers. With the help of community stakeholders and clinical genetic professionals the investigators will: * adapt and refine a culturally relevant online educational genetic counseling program for at-risk African Americans * Test the effects of the educational program * collaborate with community leaders and clinical genetic professionals to translate study findings, develop a road map for dissemination to the community, and identify barriers to prepare for future trials. Participants from Detroit Research on Cancer Survivor group will be offered enrollment. Once consent is obtained, questionnaires will be completed before an online genetic counselling intervention immediately after, and at 3 months

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: Culturally adapted Online Genetic Counseling and Testing Information — Testing the effects of the educational intervention designed to increase the uptake of genetic counseling testing among at-risk African American survivors

Primary Outcomes

  • Uptake of genetic counseling and genetic testing (3 month follow Up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-18
Completion: 2029-07
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Felicity WK Harper, Ph.D (PRINCIPAL_INVESTIGATOR) - Barbara Ann Karmanos Cancer Institute
Contact Information
Study Contact:
Jasminder Phalore, MPH
313-576-9735
phalorej@karmanos.org
Jasminder Phalore, MPH
313-576-9735
phalorej@karmanos.org
Karmanos Cancer Institute
Hayley Thompson, Ph.D
Karmanos Cancer Institute
Interventions
  • Behavioral: Culturally adapted Online Genetic Counseling and Testing Information — Testing the effects of the educational intervention designed to increase the uptake of genetic counseling testing among at-risk African American survivors
Study Locations (1 sites)
Karmanos Cancer Institute, Detroit, Michigan 48201 United States
Eligibility Criteria
Inclusion Criteria: * Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS) * Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1/1/2013 * have received or currently receiving care at Karmanos Cancer Institute * meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below Female breast 1. personal diagnosis at age ≤50 2. personal history of the triple-negative subtype 3. at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age \<50 4. at least 1 close relative diagnosed with ovarian cancer 5. 2+ close relatives diagnosed with breast or prostate cancer 6. age \<50 AND another primary breast cancer at any age 7. 2+ primary breast cancers at any age OR Prostate 1. personal history of high-risk or very high-risk prostate cancer 2. personal history of regional or metastatic prostate cancer 3. personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age \<60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer) OR Colorectal 1. personal diagnosis at age ≤50 2. at least 1 close relative diagnosed with HNPCC at age \<50 3. at least 2 close relatives diagnosed with an HNPCC cancer at any age 4. colorectal and \>=1 primary endometrial, ovarian, gastric, pancreatic, or prostate Exclusion Criteria: * Previous genetic counseling and/or testing
Conditions Depression
Phase NA
Enrollment 110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The research aims to investigate the efficacy of a narrative therapy group in reducing depressive symptoms among older people. This study adopts a mixed methods research design, involving both quantitative and qualitative approaches. In the quantitative study, a randomised controlled trial will compare a narrative therapy group with a waitlist control group to determine whether an eight-session narrative therapy group can reduce depressive symptoms in older people. The eight-session narrative therapy group will be delivered by a trained and experienced social worker or counsellor, and intervention outcomes will be assessed before and after the intervention using a standardised assessment tool for depressive symptoms. The qualitative study aims to examine the benefits, advantages, and limitations of the narrative therapy group from the users' perspective.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Narrative therapy group — Narrative therapy group consists of 8 sessions, with one session will be conducted per week, with each session lasting for about 90 minutes. A social worker and a counsellor will be recruited to run narrative groups at collaborative elderly centres. The narrative therapy group provides the following intervention strategies: engagement, de-construction, re-construction, and co-construction of personal identities. A standardized program manual of this narrative group will be developed by the research team. The social workers delivering the narrative therapy group in this project will receive the program manuals, training and supervision from the project team and an experienced clinical psychologist to ensure that the intervention groups follow the program manual.
  • Other: Treatment as usual (TAU) — Waitlist control group will receive will receive treatment as usual provided by the elderly centre, including recreational activities and interest classes, at the initial stage and will receive a brief narrative therapy program at a later stage

Primary Outcomes

  • Chinese Beck Depression Inventory-II (BDI) (Before and after the 8-week intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-10
Completion: 2026-08-31
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City University of Hong Kong
Principal Investigators:
  • Kim-wan Daniel Young, PhD (PRINCIPAL_INVESTIGATOR) - City University of Hong Kong
Contact Information
Study Contact:
Kim-wan Daniel Young, PhD
+852 3442 8954
dkwyoung@cityu.edu.hk
Kim-wan Daniel Young, PhD
34428954
dkwyoung@cityu.edu.hk
City University of Hong Kong
Interventions
  • Behavioral: Narrative therapy group — Narrative therapy group consists of 8 sessions, with one session will be conducted per week, with each session lasting for about 90 minutes. A social worker and a counsellor will be recruited to run narrative groups at collaborative elderly centres. The narrative therapy group provides the following intervention strategies: engagement, de-construction, re-construction, and co-construction of personal identities. A standardized program manual of this narrative group will be developed by the research team. The social workers delivering the narrative therapy group in this project will receive the program manuals, training and supervision from the project team and an experienced clinical psychologist to ensure that the intervention groups follow the program manual.
  • Other: Treatment as usual (TAU) — Waitlist control group will receive will receive treatment as usual provided by the elderly centre, including recreational activities and interest classes, at the initial stage and will receive a brief narrative therapy program at a later stage
Study Locations (1 sites)
City University of Hong Kong, Kowloon Tong, Hong Kong Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. aged 60 years or above; 2. exhibiting depressive symptoms as assessed using a standardised assessment tool, namely the Chinese Beck Depression Inventory-II (BDI; Byrne et al., 2004), with a BDI score between 10 and 30; 3. being a service user of an elderly centre; and 4. providing informed consent to participate in this research. Exclusion Criteria: 1. Individuals with severe depression (i.e. a BDI score ≥ 31), dementia, psychosis, or self-reported suicidal thoughts are excluded from this study; and 2. Individuals currently receiving a therapeutic intervention are not excluded from this study.
Conditions Bipolar Disorder (BD)
Phase PHASE1, PHASE2
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The HPS-6 (Hypomanic Personality Scale, 6 item version) could prove to be a valuable candidate for screening measures of high risk individuals. In the following study, we aim to validate and adapt the HPS-6 for the Romanian population.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Sequential Primary purpose: Screening Masking/blinding: Triple

Interventions / Regimen

  • Diagnostic Test: Hypomanic Personality Scale - 6 — A brief instrument, such as the HPS-6, with high specificity can help navigate specialists towards a correct diagnosis or recognize risk patterns in Bipolar Spectrum Individuals.

Primary Outcomes

  • Hypomanic Personality Scale - 6 (HPS-6) (Baseline and one month later for re-test measures (in order to account for test-retest reliability))
  • Mood Disorder Questionnaire (MDQ) (Baseline)
  • Behavioral Inhibition System / Behavioral Activation System scales (BISBAS) (One month after Baseline)
  • Positive and Negative Affect Schedule (PANAS) (One month after Baseline.)
  • Negative Urgency, Premeditation, Perseverance, Sensations Seeking, and Positive Urgency - Impulsive Behavior Scale (UPPS-P) (One month after Baseline)
  • Affective Lability Scale - Short Form (ALS-18) (One month after Baseline)
  • Positive Overgeneralization (POG) (One month after Baseline.)
  • Altman Self-Rating Mania Scale (ASRM) (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-09-22
Completion: 2026-07
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Babes-Bolyai University
Contact Information
Study Contact:
Renata Gheorghiu, PhD Student
Romania: 0731 739 485
renata.gheorghiu@ubbcluj.ro
Renata Gheorghiu, PhD Student
0731739485
renata.gheorghiu@ubbcluj.ro
Babeș-Bolyai University
Interventions
  • Diagnostic Test: Hypomanic Personality Scale - 6 — A brief instrument, such as the HPS-6, with high specificity can help navigate specialists towards a correct diagnosis or recognize risk patterns in Bipolar Spectrum Individuals.
Study Locations (1 sites)
Babeș-Bolyai University, Cluj-Napoca, 400084 Romania
Eligibility Criteria
Inclusion Criteria: * 18-50 years of age * Not at high risk of suicide (current) * Not high SUDs / AUDs (current) * Native Romanian speaker * Cognitive abilities intact (reading comprehension of items) Exclusion Criteria: * High risk of suicide (current) * High SUDs / AUDs (current)
Conditions Hypertension, Diabetes
Phase NA
Enrollment 1110
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Hypertension and diabetes represent significant and growing public health challenges in Nepal, particularly in underserved communities. Traditional individual-based care approaches may not adequately address the multifaceted needs of patients with these chronic conditions in resource-limited settings. The group care model, which combines peer support, education, and clinical care, offers a promising alternative that could enhance patient outcomes. This protocol outlines a dual cluster randomized controlled trial (DRCT) using a hybrid type II design to evaluate the effectiveness of a group care model for improving the control and management of hypertension and diabetes in four municipalities in Nepal. The trial will also evaluate the implementation outcomes of fidelity and economic costs. The researchers will assess the effect of the group care model on clinical outcomes. The primary outcomes will be the proportion of patients with controlled versus uncontrolled blood pressure (among patients with hypertension) and the proportion of patients with controlled versus uncontrolled hemoglobin A1c (among patients with diabetes) at 6 and 12 months. The researchers will conduct a three-arm comparison (control vs. low intensity strategies vs. high intensity strategies), with additional pairwise contrasts to examine differences in effectiveness. The researchers will also evaluate intervention fidelity in the two intervention groups and conduct an economic analysis. Each cluster, representing a health facility, will be randomly allocated to one of the three arms after baseline data collection and prior to initiating the intervention phase. The low intensity arm will receive the group care model with standard implementation support, while the high intensity arm will receive the group care model with enhanced implementation strategies. The control arm will continue with the standard of care offered in the nearest health facility, including hypertension and diabetes detection and management based on PEN protocols 1 and 2. After study completion, control facilities will be offered training on the group care model.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Low Intensity Community-Based Group NCD Care — A community-based group care model for hypertension and diabetes management, facilitated by HWs and FCHVs, delivered with low-intensity implementation strategies, including: * Clinical supervision to FCHVs and HWs at baseline, midline and endline only * Remote quarterly refresher sessions on group care model * Initial governmental meetings * One-time training on data entry forms at initiation of study
  • Behavioral: High Intensity Community-Based Group NCD Care — A community-based group care model for hypertension and diabetes management, facilitated by HWs and FCHVs, delivered with high-intensity implementation strategies including: * Frequent intensive clinical supervision for HWs/FCHVs * Quarterly refresher sessions and monthly remote check-ins about group care * Partnering with municipalities through regular meetings, goal to supplement programming with local governmental funding * Intensive data review (quarterly) with structured feedback and regular quality checks of data entry

Primary Outcomes

  • Proportion of patients with NCD Control from baseline to follow-up (at 6 months from start of intervention, and 12 months from start of intervention)
  • Fidelity Score (at 6 months and at 12 months from start of intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-29
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Collaborators: Kathmandu University School of Medical Sciences
Principal Investigators:
  • Neha Limaye (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Nishtha Balla, MPH
+977 9841049208
nishtha.balla@dhulikhelhospital.org
Archana Shrestha
+977 9801002245
archana@kusms.edu.np
Archana Shrestha, PhD
archana@kusms.edu.np
Dhulikhel Hospital
Interventions
  • Behavioral: Low Intensity Community-Based Group NCD Care — A community-based group care model for hypertension and diabetes management, facilitated by HWs and FCHVs, delivered with low-intensity implementation strategies, including: * Clinical supervision to FCHVs and HWs at baseline, midline and endline only * Remote quarterly refresher sessions on group care model * Initial governmental meetings * One-time training on data entry forms at initiation of study
  • Behavioral: High Intensity Community-Based Group NCD Care — A community-based group care model for hypertension and diabetes management, facilitated by HWs and FCHVs, delivered with high-intensity implementation strategies including: * Frequent intensive clinical supervision for HWs/FCHVs * Quarterly refresher sessions and monthly remote check-ins about group care * Partnering with municipalities through regular meetings, goal to supplement programming with local governmental funding * Intensive data review (quarterly) with structured feedback and regular quality checks of data entry
Study Locations (1 sites)
Dhulikhel Hospital, Dhulikhel, Nepal
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years and above living in the catchment areas of the 37 health facilities participating in the trial, across the 4 specified municipalities * Individuals who are newly diagnosed with hypertension (defined as systolic blood pressure 140 mmhg or higher and/or diastolic blood pressure 90 mmHg or higher.) and/or diabetes (defined as fasting blood glucose ≥126 mg/dL, random blood glucose ≥200 mg/dL, or Hgb A1c≥6.5). * Individuals with previously known diagnoses of hypertension and/or diabetes with records from health facilities record or patient card of individuals. * Residents of the catchment areas served by the enrolled health facilities in the study sites. Exclusion Criteria: * Individuals with physical or verbal disabilities that would impede their participation in the intervention activities, such as attending and participating in group discussions, counseling sessions, or self-reporting during data collection. * Pregnant women * People who may migrate within a year
Conditions Behavior, Risk
Phase NA
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This randomized trial aims to test the effects of co-created breast cancer counter marketing intervention messages for reducing alcohol consumption and impacting awareness and beliefs about the breast cancer risks from alcohol consumption in young adult women.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Behavioral: Alcohol and Breast Cancer Risk Messages — Participants will be randomized in a 1:1 ratio to the intervention or control arm. In the intervention arm, participants will receive the co-created intervention content. The investigators co-created the intervention content, including visuals and text, through focus groups with young adult women and refined the draft content based on additional feedback from focus groups, thereby ascertaining the views of young adult women. The intervention content aligns with a conceptual framework and includes messaging with the following themes: 1) Risks of breast cancer from alcohol consumption; 2) Efficacy content promoting behavior change; 3) Relevance to young adult women; 4) Mechanisms through which alcohol consumption increases breast cancer risk; 5) Exposing the alcohol industry's deceptive marketing practices; 6) Comparisons to other behavioral risk factors for cancer.
  • Behavioral: Skin Cancer Risk Messages — Participants in the control arm will receive text only content about skin cancer risk and prevention. This is based on intervention trials in other cancer prevention areas (e.g., tobacco) where the investigators used this type of control, provides a contact-matched comparison relative to the intervention arm, and ensures consistency of the protocol (e.g., timing of completion and content of measures to be completed) across the trial arms.

Primary Outcomes

  • Alcohol Consumption (12 weeks post intervention)
  • Daily Alcohol Consumption (12 weeks post intervention)
  • Intentions to Reduce Alcohol Consumption (12 weeks post intervention)
  • Alcohol and Breast Cancer Risk Beliefs (12 weeks post intervention)
  • Alcohol and Breast Cancer Efficacy Beliefs (12 weeks post intervention)
  • Awareness of the Risks of Breast Cancer from Drinking Alcohol (12 weeks post intervention)
  • Transdermal Alcohol Concentration (12 weeks post intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-19
Completion: 2027-07-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ohio State University Comprehensive Cancer Center
Collaborators: Breast Cancer Research Foundation
Principal Investigators:
  • Darren Mays, MPH, PhD (PRINCIPAL_INVESTIGATOR) - Ohio State University Comprehensive Cancer Center
Contact Information
Study Contact:
The Ohio State University Comprehensive Cancer Center
800-293-5066
OSUCCCClinicaltrials@osumc.edu
Darren Mays, MPH, PhD
614-366-2953
Darren.Mays@osumc.edu
Ohio State University Comprehensive Cancer Center
Darren Mays, MPH, PhD
Ohio State University Comprehensive Cancer Center
Interventions
  • Behavioral: Alcohol and Breast Cancer Risk Messages — Participants will be randomized in a 1:1 ratio to the intervention or control arm. In the intervention arm, participants will receive the co-created intervention content. The investigators co-created the intervention content, including visuals and text, through focus groups with young adult women and refined the draft content based on additional feedback from focus groups, thereby ascertaining the views of young adult women. The intervention content aligns with a conceptual framework and includes messaging with the following themes: 1) Risks of breast cancer from alcohol consumption; 2) Efficacy content promoting behavior change; 3) Relevance to young adult women; 4) Mechanisms through which alcohol consumption increases breast cancer risk; 5) Exposing the alcohol industry's deceptive marketing practices; 6) Comparisons to other behavioral risk factors for cancer.
  • Behavioral: Skin Cancer Risk Messages — Participants in the control arm will receive text only content about skin cancer risk and prevention. This is based on intervention trials in other cancer prevention areas (e.g., tobacco) where the investigators used this type of control, provides a contact-matched comparison relative to the intervention arm, and ensures consistency of the protocol (e.g., timing of completion and content of measures to be completed) across the trial arms.
Study Locations (1 sites)
Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
Eligibility Criteria
Inclusion Criteria: * Assigned female at birth. * Age 18-25 at enrollment. * Report drinking alcohol at least once in the past 30 days. * Not pregnant or intending to become pregnant by self-report. * Reside in Ohio, Michigan, Illinois, Wisconsin, or New Jersey. * Willing to complete procedures. * Able to complete procedures a, b, or c: 1. Can read, write, and converse in English. 2. Has a personal mobile smartphone with texting capabilities to receive text messages that may contain text and images. 3. For the subsample who will wear the BACTrack sensor, they must have an iPhone. At the time of this protocol, the BACTrack skyn app is only compatible with iPhones. If this expands to Android phones over the course of the study, Android phones will be eligible. Exclusion Criteria: * Assigned male at birth * Ages \<18 or \>25 at enrollment * Do not report drinking alcohol at least once in the past 30 days * Pregnant or intending to become pregnant by self-report. * Do not reside in Ohio, Michigan, Illinois, Wisconsin, or New Jersey. * Not willing to complete procedures. * Unable to complete procedures.
Conditions Triple Negative Breast Cancer (TNBC)
Phase PHASE2
Enrollment 58
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer with limited treatment options. Research suggests that using High-Intensity Focused Ultrasound (HIFU) to destroy the tumor and/or PD-1 inhibitor drugs to activate the immune system before starting chemotherapy may improve treatment effectiveness. This study aims to investigate this new approach. Objective: To evaluate the effectiveness and safety of using HIFU, with or without a PD-1 inhibitor (Sintilimab), before and during combination chemotherapy in patients with early-stage TNBC. The primary goal is to determine if this strategy can increase the rate of pathological complete response (pCR). Study Design: This is a single-center, Phase II clinical study. Approximately 40 participants with Stage II-III TNBC will be enrolled and assigned to one of two groups (cohorts) without randomization: Cohort A: Receives HIFU treatment. Two weeks later, begins standard chemotherapy (Abraxane and carboplatin) combined with the PD-1 inhibitor Sintilimab for 6 cycles. Cohort B: Receives HIFU treatment combined with a single dose of the PD-1 inhibitor Sintilimab. Two weeks later, begins the same 6 cycles of chemotherapy (Abraxane and carboplatin) combined with Sintilimab. Main Measures: The primary measure is the rate of pathological complete response (pCR), defined as the absence of invasive cancer in the breast and lymph nodes after surgery following the completion of neoadjuvant therapy. Other important measures include: The ability of the treatment to activate the immune system (measured by changes in CD8+ T cells or IFN-γ). The percentage of patients whose tumors shrink significantly (Objective Response Rate). How long patients live without their cancer getting worse (Event-Free Survival). The rate of patients who can undergo breast-conserving surgery. The frequency and severity of side effects.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sintilimab — 200 mg, administered intravenously every 3 weeks.
  • Drug: Abraxane — 260 mg/m², administered intravenously on Day 1 of each 21-day cycle.
  • Drug: Carboplatin — AUC = 6, administered intravenously on Day 1 of each 21-day cycle.
  • Procedure: High-intensity focused ultrasound (HIFU) — HIFU sparse scanning. Under ultrasound guidance, the tumor and a 5mm margin of surrounding normal tissue are ablated using a point-by-point protocol (150W power, 3s irradiation per point, 5mm point spacing). Performed once.

Primary Outcomes

  • Pathologic Complete Response (pCR) Rate (Through study completion, an average of 1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 58 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Contact Information
Study Contact:
Wenbin Zhou, PhD
+86-138-1416-2016
zhouwenbin@njmu.edu.cn
The First Affiliated Hospital with Nanjing Medical University
Interventions
  • Drug: Sintilimab — 200 mg, administered intravenously every 3 weeks.
  • Drug: Abraxane — 260 mg/m², administered intravenously on Day 1 of each 21-day cycle.
  • Drug: Carboplatin — AUC = 6, administered intravenously on Day 1 of each 21-day cycle.
  • Procedure: High-intensity focused ultrasound (HIFU) — HIFU sparse scanning. Under ultrasound guidance, the tumor and a 5mm margin of surrounding normal tissue are ablated using a point-by-point protocol (150W power, 3s irradiation per point, 5mm point spacing). Performed once.
Study Locations (1 sites)
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu China
Eligibility Criteria
Inclusion Criteria: 1. Female patients aged ≥18 and ≤70 years. 2. Histologically confirmed invasive breast cancer, classified as Stage II-III triple-negative breast cancer (TNBC) according to the 8th edition AJCC TNM staging. 3. At least one measurable lesion as per RECIST v1.1 criteria. 4. No prior chemotherapy, immunotherapy, endocrine therapy, radical surgery, or radiotherapy for breast cancer. 5. ECOG performance status of 0 or 1. 6. Adequate organ function, defined as: * Hemoglobin ≥90 g/L * White blood cell count ≥3.5×10\^9/L * Platelet count ≥100×10\^9/L * Absolute neutrophil count ≥1.5×10\^9/L * AST and ALT ≤3× upper limit of normal (ULN) * Total bilirubin ≤1.5× ULN * Serum creatinine ≤1.5× ULN * No evidence of pneumonia on chest CT 7. Adequate cardiac function, defined as: * No myocardial ischemia on ECG * NYHA class I * LVEF ≥55% on echocardiogram * Normal cardiac markers (cTnI and BNP) 8. Normal thyroid function (T3, T4, FT3, FT4, TSH). 9. Willing and able to provide written informed consent. Exclusion Criteria: 1. Male or inflammatory breast cancer. 2. Metastatic (Stage IV) breast cancer. 3. History of active autoimmune or inflammatory diseases requiring systemic treatment within the past 2 years (e.g., systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis). Exceptions: type I diabetes, hypothyroidism controlled with hormone replacement therapy, or skin disorders not requiring systemic treatment (e.g., vitiligo, psoriasis). 4. Concurrent other malignancies or history of other malignancies within the past 5 years (except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix). 5. Any other serious non-malignant disease that may compromise compliance or place the patient at risk. 6. Major surgery within 4 weeks prior to study initiation or anticipated need for major surgery during the study. 7. Prior radiotherapy, chemotherapy, targeted therapy, endocrine therapy, or major surgery for breast cancer. 8. Known hypersensitivity to any component of the study drugs. 9. Poorly controlled cardiac disease (e.g., NYHA class II+ heart failure, unstable angina, myocardial infarction within the past year, or clinically significant arrhythmias requiring intervention). 10. History of interstitial lung disease (ILD), current ILD, or suspected ILD on imaging during screening. 11. Active infections, including: * HIV positive * Active tuberculosis * Active hepatitis B (HBV-DNA \> 10\^3 IU/mL) * Active hepatitis C (HCV antibody positive with detectable HCV-RNA) 12. Active autoimmune disease requiring systemic treatment. 13. Dementia, significant intellectual impairment, or any psychiatric condition that impairs understanding of the informed consent. 14. Unhealed wounds, ulcers, or fractures within 4 weeks prior to signing consent; or any history of clinically significant bleeding or bleeding tendency. 15. Any other condition deemed by the investigator to be unsuitable for trial participation.
Conditions BPSD (Behavioral and Psycological Sympto...
Phase NA
Enrollment 56
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The dual-modal (face-to-face and online approaches), client-customized Caregivers Of dementia Processing Emotions (COPE) programme aims to 1. reduce caregivers' Expressed Emotion (EE), 2. reduce caregivers' depressive symptoms, 3. reduce the behaviourally interactive social dynamic of maladaptation (i.e., dysfunctional dyadic relationship and quality of care), and 4. improve caregivers' perceived stress from PwD's Behavioral and Psychological Symptoms of Dementia (BPSD). Researchers will compare COPE to a control group (standard therapy) to examine how effective the COPE programme is. Participants will take part in: Pretest prior to COPE implementation Post-test after COPE completion Follow up test in 3 months after COPE completion

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Caregivers Of dementia Processing Emotions (COPE) — This is the first study to develop an easily accessible and feasible intervention programme, namely the Caregivers Of dementia Processing Emotions (COPE), to primarily reduce expressed emotion (EE) in family caregivers of PwD via processing one's attributional biases, dysregulated emotion, dysfunctional social dynamics using an integrative therapy. By displacing these negative thoughts and emotions, the integrative therapy has great potential to reduce the depressive symptoms in caregivers and thus mitigate their perceived stress from BPSD. In addition, the interactive social dynamics in the dementia caregiving context can be improved.

Primary Outcomes

  • Family Attitude Scale- Chinese Version (From enrollment to the end of intervention at 7 weeks and end of study at 20 weeks.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-20
Completion: 2027-03-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 56 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The University of Hong Kong
Principal Investigators:
  • Doris Sau Fung YU, PhD (PRINCIPAL_INVESTIGATOR) - The University of Hong Kong
Contact Information
Study Contact:
Doris Sau Fung YU, PhD
+852 39176319
dyu1@hku.hk
YU Sau Fung
852 + 39176319
dyu1@hku.hk
University of Hong Kong
Interventions
  • Behavioral: Caregivers Of dementia Processing Emotions (COPE) — This is the first study to develop an easily accessible and feasible intervention programme, namely the Caregivers Of dementia Processing Emotions (COPE), to primarily reduce expressed emotion (EE) in family caregivers of PwD via processing one's attributional biases, dysregulated emotion, dysfunctional social dynamics using an integrative therapy. By displacing these negative thoughts and emotions, the integrative therapy has great potential to reduce the depressive symptoms in caregivers and thus mitigate their perceived stress from BPSD. In addition, the interactive social dynamics in the dementia caregiving context can be improved.
Study Locations (1 sites)
University of Hong Kong, Hong Kong, Hong Kong
Eligibility Criteria
Inclusion Criteria: * (1) With a high level of EE as indicated by a cut-off score of 35 or above on the Family Attitude Scale (Chinese version; FAS-C) * (2) Provides care at least 4 hours per day * (3) Consent to participate * (4) No acute psychiatric illness Exclusion Criteria: * (1) With a score below 35 on the Family Attitude Scale (Chinese version; FAS-C) * (2) Provides care no more than 4 hours per day * (3) Does not consent to participate * (4) With acute psychiatric illness.
Conditions Neurologic Disorders, Schizophrenia, Bip...
Phase NA
Enrollment 600
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Neuropsychiatric disorders are extremely common, severe, and disabling conditions. In the field of psychiatry, they notably include schizophrenia, mood disorders (depressive and bipolar disorders), autism spectrum or neurodevelopmental disorders, obsessive-compulsive disorder, eating disorders, and personality disorders. In the field of neurology, one can cite neurodegenerative diseases (such as Alzheimer's disease, but also frontotemporal dementia or Parkinson's disease, which often represent frequent and challenging differential diagnoses of psychiatric disorders), focal neurological lesions (notably strokes and tumors), or epilepsy. Cognitive impairments are present in nearly all neuropsychiatric disorders and contribute significantly to disability. While impairments in working memory and attention, executive functions, and social cognition have been relatively well studied, other cognitive domains remain largely unexplored in these populations. This is particularly the case for various aspects of motivation, metacognition, conscious access, or causal (Bayesian) inference. Although these domains likely play an important role in prognosis, no consensus currently exists regarding the methods for evaluating these functions. The main objective of this study is to define a multidimensional, transdiagnostic atlas of high-level cognitive impairments-both specific and shared-across severe psychiatric disorders (notably schizophrenia, depressive disorder, bipolar disorder, autism spectrum or neurodevelopmental disorders, and obsessive-compulsive disorder) and neurological disorders (notably neurodegenerative diseases, focal neurological lesions, and epilepsy), by comparing them to healthy volunteers. The investigators also aim to investigate the progression of cognitive impairments over time, across different phases of illness (symptom stabilization or exacerbation) or therapeutic intervention, through longitudinal follow-up of patients being monitored within the recruiting center. Finally, in a more exploratory manner, the investigators aim to investigate the neural correlates of the identified cognitive impairments.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Behavioral: Cognitive assessment — This intervention consists of computerized neuropsychological assessments designed to evaluate high-level cognitive impairments. The tests cover various cognitive dimensions including motivation, metacognition, conscious access, and Bayesian causal inference. These assessments are performed using computers or tablets, aiming to build a multidimensional cognitive atlas comparing patients with severe psychiatric and neurological conditions to healthy volunteers. The tests will be progressively optimized for usability and adapted to the specific difficulties faced by patients. For some participants, additional brain imaging (MRI without contrast, EEG, MEG) may be offered optionally to identify neural correlates of cognitive deficits.
  • Behavioral: Brain MRI (optional) — Brain MRI without contrast perform at one visit to identify neural correlates of cognitive deficits
  • Behavioral: Electroencephalography (optional) — Electroencephalography performed at one visit
  • Behavioral: Magnetoencephalography (optional) — Magnetoencephalography performed at one visit

Primary Outcomes

  • Performance scores on validated computerized neuropsychological tasks assessing high-level cognitive domains (Baseline, and up to one year after baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-12
Completion: 2039-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier St Anne
Collaborators: Paris Brain Institute (ICM)
Principal Investigators:
  • Pierre BOURDILLON, Dr (PRINCIPAL_INVESTIGATOR) - Hôpital Fondation Adolphe de Rothschild
Contact Information
Study Contact:
Jacob DHOTE, Dr
+33 145658177
j.dhote@ghu-paris.fr
Fabien VINCKIER, Pr
F.VINCKIER@ghu-paris.fr
Philippe FOSSATI, Pr
0142162870
philippe.fossati@aphp.fr
Departement of Adult Psychiatry, GH Pitié Salpétrière
Interventions
  • Behavioral: Cognitive assessment — This intervention consists of computerized neuropsychological assessments designed to evaluate high-level cognitive impairments. The tests cover various cognitive dimensions including motivation, metacognition, conscious access, and Bayesian causal inference. These assessments are performed using computers or tablets, aiming to build a multidimensional cognitive atlas comparing patients with severe psychiatric and neurological conditions to healthy volunteers. The tests will be progressively optimized for usability and adapted to the specific difficulties faced by patients. For some participants, additional brain imaging (MRI without contrast, EEG, MEG) may be offered optionally to identify neural correlates of cognitive deficits.
  • Behavioral: Brain MRI (optional) — Brain MRI without contrast perform at one visit to identify neural correlates of cognitive deficits
  • Behavioral: Electroencephalography (optional) — Electroencephalography performed at one visit
  • Behavioral: Magnetoencephalography (optional) — Magnetoencephalography performed at one visit
Study Locations (3 sites)
Departement of Adult Psychiatry, GH Pitié Salpétrière, Paris, 75013 France
Groupe hospitalo-universitaire Paris Psychiatrie et Neurosciences, Paris, 75014 France
Hôpital Fondation Adolphe de Rothschild, Paris, France
Eligibility Criteria
Inclusion Criteria: For patients: * Aged over 18 years * Diagnosed with a psychiatric disorder according to ICD-10 by a psychiatrist (F10-F98) or diagnosed with a neurological disorder according to ICD-10 by a neurologist (G00-G99) * Provided written informed consent * Affiliated with a social security scheme For healthy volunteers: * Aged over 18 years * Provided written informed consent * Affiliated with a social security scheme Exclusion Criteria: For healthy volunteers: * Current diagnosis of a psychiatric disorder according to ICD-10 (F20-F98) or current prescription of a psychotropic medication, or diagnosis of a neurological disorder according to ICD-10 (G00-G99) * History of depression (F32) * Substance use disorder (excluding tobacco) * Neurological history (e.g., stroke, coma, epilepsy, neuroinflammatory or neurodegenerative disease) or identified cognitive disorder * Inability to complete cognitive testing (e.g., due to motor or sensory impairment) For participants undergoing MRI (without contrast agent): * Presence of MRI contraindications: non-MRI-compatible pacemaker, heart valve, implant, or metallic foreign body * Pregnancy at the time of MRI
Conditions Diabetes Mellitus, Type 2
Phase PHASE3
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes. The main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength. Participants will: * Receive GLP-1 RA therapy as part of their routine clinical care * Complete muscle strength assessments (hand grip strength, Timed Up and Go test) * Provide blood samples for bone turnover markers * Undergo bone mineral density testing

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Semaglutide — Semaglutide is an FDA-approved drug for the treatment of T2D at the following doses (0.25, 0.5, 1, and 2 mg) that is self-administered weekly using an autoinjector pen. The drug dosage will gradually increase every 4 weeks if tolerated to reach maintenance doses of 2 mg for semaglutide until the end of the study (6 months). If a participant cannot tolerate a dose, the highest tolerable dose will be administered, with continued efforts to increase the dose over time, gradually.

Primary Outcomes

  • Change in handgrip strength (Baseline, week4, week 8, week12, week 26.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-05-07
Completion: 2028-11
Eligibility
Age: 65 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Emory University
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Principal Investigators:
  • Thaer Idrees, MD, FSSCI (PRINCIPAL_INVESTIGATOR) - Emory University
Contact Information
Study Contact:
Thaer Idrees, MD, FSSCI
404-251-5357
thaer.idrees@emory.edu
Jaafer Zaino
jaafer.zaino@emory.edu
Thaer Idrees, MD, FSSCI
404-251-5357
thaer.idrees@emory.edu
Grady Memorial Hospital
Interventions
  • Drug: Semaglutide — Semaglutide is an FDA-approved drug for the treatment of T2D at the following doses (0.25, 0.5, 1, and 2 mg) that is self-administered weekly using an autoinjector pen. The drug dosage will gradually increase every 4 weeks if tolerated to reach maintenance doses of 2 mg for semaglutide until the end of the study (6 months). If a participant cannot tolerate a dose, the highest tolerable dose will be administered, with continued efforts to increase the dose over time, gradually.
Study Locations (1 sites)
Grady Memorial Hospital, Atlanta, Georgia 30303 United States
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women aged 65 years or older * Has type 2 diabetes * Body Mass Index (BMI) ≥27 kg/m² to max 40kg/m2 (inclusive) * Hemoglobin A1c \>7% within 3 months of the first visit. * Willingness and ability to comply with all study procedures, including fasting requirements for certain visits. * No osteoporosis confirmed on DEXA scan within 12 months * Able to provide informed consent and participate in all study assessments Exclusion Criteria: * Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D * eGFR \<30 ml/min in the last 3 months * Patients with a history of treatment with anti-osteoporosis agents * Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies * Documented presence of prosthesis or devices in the spine or hip * Previous fragility fracture * Males * Moderate to severe gastroesophageal reflux disease based on patient history. * Inability to comply with the treatment protocol or to understand the consent form. * Aspartate aminotransferase (AST) \> 3 times normal or alanine aminotransferase (ALT) \> 3 times the normal * Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results. * Personal or family history of medullary thyroid carcinoma. * Personal or family history of multiple endocrine neoplasia type 2 syndrome. * Personal history of gastroparesis, celiac disease, hypogonadism, severe COPD, hypopituitarism, or Cushing's disease * Personal history of severe diabetic retinopathy. * Known serious hypersensitivity, including anaphylaxis and angioedema, to semaglutide or any of its excipients. * Any of the following drugs or treatments were used within 6 months before screening: treated with GLP-1RA, GIP analogues, pioglitazones * Concomitant treatment with GLP-1 receptor agonist therapy * Long-term intravenous, oral, and intra-articular administration of high-dose corticosteroids within 2 months before screening (more than 7 days in a row) * Use of weight control drugs or surgery that can lead to weight changes during the last 6 months before screening, or are currently in the weight loss plan and are not in the maintenance stage * Incarcerated individuals